Besides the front-line maintenance therapy, is any positive impact of poly (ADP-ribose) polymerase (PARP) inhibitors on recurrent high-grade ovarian cancer?

Yiu-Tai Li & Peng-Hui Wang

Authors
Yiu-Tai Li, Peng-Hui Wang